ABS-201
Phase 1/2 registry
Company reports Phase 1/2a; Phase 2 STORYLINE planned
Since , the date of the source that reports this phase.
Summary
ABS-201 is a program from Absci. It is being developed for androgenetic alopecia, a common form of hair loss (women's cohort opened). ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT07317544. The company reports Phase 1/2a; Phase 2 STORYLINE planned. The AI role named in the source is AI-designed therapeutic. Registry records: NCT07317544, Phase 1/2, recruiting, updated Oct 28, 2026. About the company, based in United States: Integrated Drug Creation platform combining generative AI with wet-lab validation to design antibodies; lead ABS-201 (anti-PRLR) is in Phase 1/2. The latest dated source is from Oct 13, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Absci
- Indication
- Androgenetic alopecia, a common form of hair loss (women's cohort opened)
- Therapeutic area
- Dermatology
- AI role
- AI-designed therapeutic
- Phase in the source
- Phase 1/2a; Phase 2 STORYLINE planned, as of Oct 13, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Company
“ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform.”
Trial records
- NCT07317544 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1/2a; Phase 2 STORYLINE planned
-
NCT07317544 record updated
Phase 1/2, Recruiting
About Absci
Integrated Drug Creation platform combining generative AI with wet-lab validation to design antibodies; lead ABS-201 (anti-PRLR) is in Phase 1/2.
Spot an error? Tell me and I'll fix it.